CGON Company Profile and Key Details

Short-term trend indicators are bearishly aligned (SMA20 4.14%, SMA50 13.79%, SMA200 52.02%). The stock’s 14-day RSI is 58.08 (neutral), while the ATR of 2.87 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -6.48% below its high and over 279.12% above its low. Average 10-day trading volume of 1.09 million shares is in line with the 3-month average of 1.06 million, indicating normal recent market interest.

CG Oncology, Inc. Common stock has 80.67 million shares outstanding. The public float is 65.44 million shares, elevated short interest at 17.28% of float. This equals 13.21 million shares. The short ratio is 14.15 days. Institutional investors hold 113.95% of the float. Insiders own 1.17%. Song Hong Fang holds 2.90 million shares, Liu Brian Guan-Chyun has 1.52 million shares and Decheng Capital Global Life Sciences Fund IV, L.P. has 400.00 thousand shares. Over the past six months, insider transactions show net selling. They sold 59.84 thousand shares across 9 transactions.

CG Oncology, Inc. Common stock last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$1.77. This means the shares are trading below this model’s fair value.

Wall Street analysts project EPS growth of -18.19% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 11 Strong Buy ratings, 11 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $90.00 to $47.00. The high target offers 43.31% upside. The low target suggests -25.16% downside. The mean target is $68.41. This offers 8.93% upside. CG Oncology, Inc. Common stock earnings surprise history is a consistent trend of beating forecasts. The quarter that ended November 14, 2025, missed forecasts by 0.0%. The prior quarter beat by 0.0%. Over the last six quarters, Apple has recorded several small beats. These include -33.33% in August 08, 2024.

CG Oncology, Inc. Common stock (NASDAQ:CGON) closed at $62.80 USD, gaining $1.51 (2.46%) from the previous close of $61.29. The stock is currently within 5% of its 52-week high $14.80 and $63.89. With a market capitalization of about $5.30 billion, CG Oncology, Inc. Common stock is classified as a mid-cap and shows market-like volatility (beta ~1.19). Key stats such as the average daily volume over the past year has been around 1.09 million shares, in line with its 52-week average. Headquartered in Irvine, DE, CG Oncology, Inc. Common stock operates in the Healthcare sector and the Biotechnology industry. Led by CEO Arthur Kuan, the company employs approximately 113 people and listed since January 25, 2024. CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer.

Our AI price prediction model suggests that CG Oncology, Inc. Common stock stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 6.66%, with price expected at $66.98 by March 23, 2026, within a range of $65.26 to $68.76 3-Month Outlook: Projected rise of 69.67%, reaching $106.55 by June 05, 2026, with a range of $105.49 to $107.84. 1-Year Outlook: Projected loss of -0.92%, with price at $62.22 by March 09, 2027, within a range of $59.16 to $65.16.

CG Oncology, Inc. Common stock (NASDAQ:CGON) shares are up 31.72% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows CG Oncology, Inc. Common stock trading at a premium to the broader market with a P/E of -29.87. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $68.24, suggesting 8.66% upside. Our AI forecast model points to short-term strength (6.66% over two weeks), a medium-term rise (69.67% over three months), and a longer-term loss (-0.92% over one year), with expected trading ranges indicating moderate volatility.

CG Oncology, Inc. Common stock trades at a P/E ratio of -29.87, slightly below the S&P 500 average, with a price-to-sales ratio of 1300.18 and a price-to-book ratio of 6.39 trading at moderately above to book value. The P/FCF stands at -39.65, also below market averages.